title: SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study.
abstract: OBJECTIVE
  To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT).
  
  
  BACKGROUND
  Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT.
  
  
  METHODS
  Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients were divided into 3 groups based on the duration of ADT (6, 12-18, ≥24 months) and compared to a control group without ADT. MetS was defined according to NCEP ATP III criteria. Osteoporosis was assessed by DEXA.
  
  
  RESULTS
  A total of 270 pts, treated from November 2011 to October 2012, were included. Of these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was significantly higher (71.3 vs. 69.38 years, p = 0.028). MetS prevalence was 50% in the control group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after 12-18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA. Of those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis.
  
  
  CONCLUSIONS
  The prevalence of MetS in pts with PCa treated with radical RT was higher (47%) than in the general population. However, there were no significant differences in the duration of ADT administration. The prevalence of osteoporosis was low. These findings suggest that the prevalence of MetS in PCa patients may be higher than previously reported.
authors.affiliation: Department of Radiation Oncology, Rey Juan Carlos Hospital, Madrid, Spain.
authors.forename: Pilar Ma
authors.initials: PM
authors.lastname: Samper Ots
authors.affiliation: Department of Radiation Oncology, Infanta Cristina Hospital, Madrid, Spain.
authors.forename: Julia Luisa
authors.initials: JL
authors.lastname: Muñoz García
authors.affiliation: Department of Radiation Oncology, Infanta Cristina Hospital, Madrid, Spain.
authors.forename: Yesika
authors.initials: Y
authors.lastname: Ríos Kavadoy
authors.affiliation: Department of Radiation Oncology, Gómez Ulla Hospital, Spain.
authors.forename: Ma Luz
authors.initials: ML
authors.lastname: Couselo Paniagua
authors.affiliation: Department of Radiation Oncology, Navarra Hospital, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Villafranca Iturre
authors.affiliation: Department of Radiation Oncology, Reina Sofía Hospital, Spain.
authors.forename: Milagrosa
authors.initials: M
authors.lastname: Rodríguez Liñán
authors.affiliation: Department of Radiation Oncology, Jiménez Díaz Hospital, Spain.
authors.forename: Ana María
authors.initials: AM
authors.lastname: Pérez Casas
authors.affiliation: Department of Radiation Oncology, Provincial Hospital of Castellón, Spain.
authors.forename: Rodrigo Muelas
authors.initials: RM
authors.lastname: Soria
authors.affiliation: Department of Radiation Oncology, Fuenlabrada Hospital, Spain.
authors.forename: Blanca Ludeña
authors.initials: BL
authors.lastname: Martínez
authors.affiliation: Department of Radiation Oncology, General University Hospital of Valencia, Spain.
authors.forename: José López
authors.initials: JL
authors.lastname: Torrecilla
authors.affiliation: Department of Radiation Oncology, Fundación IVO Valencia, Spain.
authors.forename: Manuel Casaña
authors.initials: MC
authors.lastname: Giner
authors.affiliation: Department of Radiation Oncology, La Princesa Hospital, Spain.
authors.forename: Almudena Zapatero
authors.initials: AZ
authors.lastname: Laborda
authors.affiliation: Department of Radiation Oncology, Juan Ramón Jiménez Hospital, Spain.
authors.forename: Ma Magdalena Márquez
authors.initials: MM
authors.lastname: García-Salazar
keywords: Androgen deprivation therapy; Metabolic syndrome; Osteoporosis; Prostate cancer